Agilent Technologies has announced an expansion of its collaboration with the Centre for Cellular and Molecular Platforms (C‑CAMP), a Department of Biotechnology-supported initiative. It broadens access to advanced analytical and mass spectrometry‑based capabilities that support life sciences and therapeutic research across India.

Through this collaboration, high‑resolution analytical platforms will be made available via C‑CAMP’s shared infrastructure, supporting applications such as biotherapeutic characterization, oligonucleotide research and quantitative biomolecular analysis.

This model is designed to enable researchers from startups, academia and industry to access advanced analytical workflows and deep domain expertise without the need for direct capital investment in specialized instruments or facilities.

Agilent’s collaboration with C‑CAMP has played a catalytic role in advancing India’s biopharma ecosystem by enabling world‑class, regulatory‑aligned characterization of biologics and biosimilars across therapeutic applications.

The engagement aligns with C‑CAMP’s vision towards building a connected ecosystem that supports science‑to‑impact pathways, while leveraging Agilent’s expertise in analytical workflows and technology enablement.

“India is a strategic priority for Agilent and partnerships like this are central to how we expand access to critical scientific capabilities,” said Nandakumar Kalathil, Country General Manager, Agilent India. “Working with C‑CAMP allows a broader community of researchers to leverage advanced analytical workflows that support high‑quality, reproducible science across discovery and translational research.”

Source: IndiaMed Today - May 12,2026